.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Endovascular thrombectomy has traditionally been offered to carefully selected stroke patients with relatively small infarct cores. Evidence from trials such as SELECT2, RESCUE-Japan LIMIT, ANGEL-ASPECT and related studies has expanded the treatment population to include some patients with large ischemic cores. A 2024 standards and guidelines statement from the Society of NeuroInterventional Surgery synthesised the emerging evidence and concluded that selected patients with anterior-circulation large-vessel occlusion and large infarct cores can benefit from thrombectomy within 24 hours. The recommendations emphasise factors such as age, NIHSS, baseline disability, imaging features and treatment timing rather than using infarct-core size alone as an absolute exclusion. For HCPs, the practical implication is major: systems should avoid therapeutic nihilism when a patient presents with a large established infarct but still has a treatable occlusion and a profile matching the evidence base. Selection should remain rigorous, and local stroke pathways need rapid imaging and specialist review. The topic directly matches IANCON's “grey zones” in vascular neurology and evolving endovascular treatment.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Endovascular thrombectomy has traditionally been offered to carefully selected stroke patients with relatively small infarct cores. Evidence from trials such as SELECT2, RESCUE-Japan LIMIT, ANGEL-ASPECT and related studies has expanded the treatment population to include some patients with large ischemic cores. A 2024 standards and guidelines statement from the Society of NeuroInterventional Surgery synthesised the emerging evidence and concluded that selected patients with anterior-circulation large-vessel occlusion and large infarct cores can benefit from thrombectomy within 24 hours. The recommendations emphasise factors such as age, NIHSS, baseline disability, imaging features and treatment timing rather than using infarct-core size alone as an absolute exclusion. For HCPs, the practical implication is major: systems should avoid therapeutic nihilism when a patient presents with a large established infarct but still has a treatable occlusion and a profile matching the evidence base. Selection should remain rigorous, and local stroke pathways need rapid imaging and specialist review. The topic directly matches IANCON's “grey zones” in vascular neurology and evolving endovascular treatment.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
